We are live on
!
Find out more
ACM
ACT Capital Management Portfolio holdings
AUM
$127M
This Fund
S&P 500
This Quarter
Est. Return
+34.85%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$124M
AUM Growth
–
Cap. Flow
+$115M
Cap. Flow
% of AUM
93.08%
Top 10 Holdings %
Top 10 Hldgs %
67.23%
Holding
58
New
58
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Krystal Biotech
KRYS
|
+$12.7M |
| 2 |
Chevron
CVX
|
+$12M |
| 3 |
ExxonMobil
XOM
|
+$9.57M |
| 4 |
TG Therapeutics
TGTX
|
+$8.78M |
| 5 |
Viking Therapeutics
VKTX
|
+$7.3M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.01% |
| 2 | Energy | 21.39% |
| 3 | Consumer Discretionary | 4.59% |
| 4 | Technology | 2.59% |
| 5 | Financials | 1.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Krystal Biotech
KRYS
$10.4B
| $14.9M | 12.06% |
+60,500
| New | +$12.7M |
|
|
2
Chevron
CVX
$378B
| $12M | 9.67% |
+78,500
| New | +$12M |
|
|
3
ExxonMobil
XOM
$642B
| $9.93M | 8.03% |
+82,500
| New | +$9.57M |
|
|
ABVX
4
Abivax
ABVX
$11.2B
| $8.62M | 6.97% |
+63,900
| New | +$6.97M |
|
|
5
TG Therapeutics
TGTX
$8.53B
| $8.02M | 6.48% |
+268,875
| New | +$8.78M |
|
|
6
Viking Therapeutics
VKTX
$4.05B
| $7.25M | 5.86% |
+206,100
| New | +$7.3M |
|
7
Celcuity
CELC
$4.01B
| $6.33M | 5.11% |
+63,415
| New | +$5.21M |
|
8
Amazon
AMZN
$2.49T
| $5.68M | 4.59% |
+24,600
| New | +$5.63M |
|
9
Nuvation Bio
NUVB
$2.32B
| $5.47M | 4.42% |
+610,500
| New | +$3.78M |
|
10
Arrowhead Research
ARWR
$12B
| $4.98M | 4.03% |
+75,000
| New | +$3.68M |
|
11
Cytokinetics
CYTK
$10.9B
| $4.1M | 3.31% |
+64,500
| New | +$4.01M |
|
12
Structure Therapeutics
GPCR
$3.46B
| $2.68M | 2.17% |
+38,500
| New | +$1.57M |
|
13
Grayscale Bitcoin Trust
GBTC
$9.75B
| $2.35M | 1.9% |
+34,400
| New | +$2.7M |
|
|
FIGR
14
Figure Technology Solutions
FIGR
$6.37B
| $2.35M | 1.9% |
+57,500
| New | +$2.3M |
|
15
Spotify
SPOT
$102B
| $2.32M | 1.88% |
+4,000
| New | +$2.5M |
|
16
Energy Transfer Partners
ET
$68.5B
| $2.19M | 1.77% |
+133,100
| New | +$2.22M |
|
17
Nektar Therapeutics
NKTR
$2.41B
| $2.16M | 1.75% |
+51,200
| New | +$2.87M |
|
18
Olema Pharmaceuticals
OLMA
$1.05B
| $1.34M | 1.08% |
+53,500
| New | +$952K |
|
19
IBM
IBM
$204B
| $1.33M | 1.08% |
+4,500
| New | +$1.35M |
|
20
STAAR Surgical
STAA
$1.14B
| $1.28M | 1.04% |
+55,500
| New | +$1.43M |
|
21
Regenxbio
RGNX
$622M
| $1.19M | 0.96% |
+82,500
| New | +$1.03M |
|
22
Bloom Energy
BE
$53.5B
| $1.13M | 0.91% |
+13,000
| New | +$1.37M |
|
23
Warrior Met Coal
HCC
$4.26B
| $1.06M | 0.86% |
+12,000
| New | +$902K |
|
24
EOG Resources
EOG
$74.7B
| $1.05M | 0.85% |
+10,000
| New | +$1.07M |
|
|
SNDK
25
Sandisk
SNDK
$189B
| $831K | 0.67% |
+3,500
| New | +$701K |
|
Similar funds
CF
MF
SAP
PIP
VDC
PA
S
SIM
ACT Capital Management's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for ACT Capital Management, which disclosed 58 positions worth $124M. Its ten largest holdings account for 67% of the portfolio.
Its largest position is Krystal Biotech: 60,500 shares worth $14.9M.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, followed by Energy and Consumer Discretionary.
- ACT Capital Management's largest Q4 2025 buy was Krystal Biotech: 60,500 shares worth $14.9M.
- ACT Capital Management's ten largest holdings make up 67% of its $124M portfolio in Q4 2025.
- ACT Capital Management disclosed 58 positions in Q4 2025, its first 13F filing on record.
Based on ACT Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.